Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 29, Number 10—October 2023
Dispatch

Mpox in Children and Adolescents during Multicountry Outbreak, 2022–2023

Ana Hoxha1Comments to Author , Steven M. Kerr1, Henry Laurenson-Schafer, Nikola Sklenovská, Bernadette Basuta Mirembe, Ingrid Hammermeister Nezu, Patricia Ndumbi, Julia Fitzner, Maria Almiron, Marcelo Vila, Richard Pebody, Aisling M. Vaughan, Joana M. Haussig, Luis Alves de Sousa, Okot Charles Lukoya, Olaniyi Felix Sanni, Pierre Nabeth, Jeremias Domingos Naiene, Masaya Kato, Tamano Matsui, Krutika Kuppalli, Peter Omondi Mala, Rosamund F. Lewis, Olivier le Polain de Waroux, Boris I. Pavlin, and WHO Mpox surveillance and Analytics Team
Author affiliations: Health Emergencies Programme, World Health Organization (WHO), Geneva, Switzerland (A. Hoxha, H. Laurenson-Schafer, N. Sklenovska, B.B. Mirembe, I.H. Nezu, P. Ndumbi, J. Fitzner, K. Kuppalli, P.O. Mala, R.F. Lewis, O. le Polain de Waroux, B.I. Pavlin); CPC Analytics, Berlin, Germany (S.M. Kerr); WHO Regional Office for the Americas, Washington, DC, USA (M. Almiron, M. Vila); WHO Regional Office for Europe, Copenhagen, Denmark (R. Pebody, A.M. Vaughan); European Centre for Disease Prevention and Control, Solna, Sweden (J.M. Haussig, L. Alves de Sousa); WHO Regional Office for Africa, Brazzaville, Republic of the Congo (O.C. Lukoya, O.F. Sanni); WHO Regional Office for the Eastern Mediterranean, Cairo, Egypt (P. Nabeth, J.D. Naiene); WHO Regional Office for South-East Asia, Delhi, India (M. Kato); WHO Regional Office for the Western Pacific, Manila, Philippines (T. Matsui)

Main Article

Table 2

Main symptoms of mpox in children and adolescents reported globally among cases with symptom data, January 2022–May 2023*

Characteristic No. (%) case-patients, by age group
0–4 y 5–12 y 13–17 y Total
Total
156 (28.8)
 157 (28.9)
 229 (42.3)
 542 (100)
Any symptoms
Yes 124 (79.5) 132 (84.1) 216 (94.3) 472 (87.1)
No
 32 (20.5)
 25 (15.9)
 13 (5.7)
 70 (12.9)
Any rash
Yes 77 (49.4) 84 (53.5) 164 (71.6) 325 (60.0)
No
 79 (50.6)
 73 (46.5)
 65 (28.4)
 217 (40.0)
Genital rash
Yes 8 (5.1) 11 (7.0) 54 (23.6) 73 (13.5)
No
 148 (94.9)
 146 (93.0)
 175 (76.4)
 469 (86.5)
Fever
Yes 66 (42.3) 73 (46.5) 131 (57.2) 270 (49.8)
No
 90 (57.7)
 84 (53.5)
 98 (42.8)
 272 (50.2)
Headache
Yes 18 (11.5) 44 (28.0) 96 (41.9) 158 (29.2)
No
 138 (88.5)
 113 (72.0)
 133 (58.1)
 384 (70.8)
Any lymphadenopathy
Yes 4 (2.6) 11 (7.0) 45 (19.7) 60 (11.1)
No 152 (97.4) 146 (93.0) 184 (80.3) 482 (88.9)

*Percentages are calculated by column for each symptom.

Main Article

1These first authors contributed equally to this article.

Page created: August 30, 2023
Page updated: September 20, 2023
Page reviewed: September 20, 2023
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external